OBJECTIVE: To evaluate the efficacy and safety of sirolimus in patients after liver transplantation. METHODS: Retrieved from CNKI, VIP, Wanfang Database, CBM, SprmgerLink and PubMed from 2000 to 2009, domestic and foreign literatures on the application of sirolimus in patients after liver transplantation were included and analyzed using evidence-based pharmacy. Meta-analysis was performed using RevMan 4.2.2 software. RESULTS: A total of 2 884 literatures were retrieved and 7 literatures were included in study. The results of Meta-analysis showed: no significant difference in survival of patient and liver was found among patients whether or not taking sirolimus after liver transplantation (P=0.69). Sirolimus could reduce the acute rejection (P=0.04) and improve renal function (P＜0.000 01). CONCLUSION: Sirolimus could reduce acute rejection in patients after liver transplantation and improve renal function. However, there is no significant difference in survival rate of liver.%目的:运用循证药学方法评价西罗莫司在肝移植患者中的有效性及安全性.方法:检索2000-2009年的中国期刊网全文数据库(CNKI)、维普中文科技期刊全文数据库(VIP)、万方数据医药信息系统、中国生物医学文献服务系统(CBM)、SpringerLink和PubMed等发表的西罗莫司在肝移植患者中应用的中、外文献,进行循证药学分析,采用RevMan 4.2.2软件进行Meta分析.结果:共检索到文献2 884篇,有7篇文献纳入研究.Meta分析显示,肝移植术后使用西罗莫司与否在患者存活情况和移植肝存活情况方面的作用差异无统计学意义(P=0.69),但使用西罗莫司可以减少急性排斥反应的发生(P=0.04),改善患者肾功能(P＜0.000 01).结论:西罗莫司可以减少肝移植术后患者急性排斥反应的发生,改善肾功能,但未改善移植肝存活率.
展开▼
